The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2021 | MagnetisMM-3: elranatamab for myeloma
Alexander Lesokhin, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the MagnetisMM-3 trial (NCT04649359), a study investigating whether single-agent elranatamab (PF-06863135) can provide clinical benefit in patients with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody that binds to two antigens, CD3 on T-cells and B-cell maturation antigen (BCMA). By bringing T-cells and cancer cells in close proximity, elranatamab can activate the T-cell killing of myeloma cells. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.
